http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-PI0603871-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5ee1fbf6aa0c4de74e2f20a01a914725 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7072 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-541 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-475 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4155 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4196 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4192 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-551 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P33-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-352 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-535 |
| filingDate | 2006-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f73dccc11a54e20c85c506b657d523b0 |
| publicationDate | 2021-01-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-PI0603871-B1 |
| titleOfInvention | pharmaceutical compositions for the treatment of trypanosomiasis and chagas disease |
| abstract | pharmaceutical compositions for the treatment of trypanosomiasis and chagas disease. the present invention relates to the treatment of trypanosomiasis in order to cure individuals infected with protozoa belonging to the trypanosomatidae family who suffer from chronic disease. more specifically, the invention deals with pharmaceutical compositions based on the association of substances having antiparasitic activity with substances that inhibit signaling pathways that enable the integration of t kdna. crossed into the host's genome. one embodiment refers to the pharmaceutical composition of the invention comprising as ingredients: (i) a pharmacologically effective amount of at least one substance with antiparasitic activity; (ii) a pharmacologically effective amount of at least one inhibitor of metabolic pathways acting to prevent the integration of t cruzi kdna into the host genome; (iii) optionally, additives compatible with any of the ingredients (i) or (ii); and (iv) a pharmaceutically acceptable carrier. a second embodiment refers to the pharmaceutical composition of the invention comprises as ingredients: (i) a pharmacologically effective amount of at least one substance with antiparasitic activity: (ii) a pharmacologically effective amount of at least inhibitor of metabolic pathways acting to prevent integration the kdna of one of the protozoa belonging to the trypanosomatidae family in the host genome; (iii) optionally, additives compatible with any of the ingredients (i) or (ii); and (iv) a pharmaceutically acceptable carrier. |
| priorityDate | 2006-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 164.